Angiochem, Inc., a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier through LRP targeting, announced today that preclinical data on two of its oncology programs, ANG1005 and ANG1007, for the treatment of brain cancers, as well as data demonstrating the utility of Angiochem's EPiC platform to achieve efficient penetration rates in the brain and in cancer tumor tissue, will be highlighted at the 101st Annual meeting of the American Association for Cancer Research 2010, April 17-21, in Washington, DC.
“Uptake of the new paclitaxel-derivative (ANG1005) by the low-density lipoprotein receptor-related protein1 (LRP1) is related to the aggressive phenotype of glioblastoma cells”
Poster Presentations:
- Abstract #4417: Tuesday, April 20, 2010, 2:00 PM - 5:00 PM, "Uptake of the new paclitaxel-derivative (ANG1005) by the low-density lipoprotein receptor-related protein1 (LRP1) is related to the aggressive phenotype of glioblastoma cells," Bertrand, et.al., Exhibit Hall A-C, Poster Section 22, Poster Board 6
- Abstract #3578: Tuesday, April 20, 2010, 9:00 AM - 12:00 PM, "New Angiochem-modified doxorubicin with increased brain penetration and efficacy against brain tumors," Demeule, et.al., Exhibit Hall A-C, Poster Section 24, Poster Board 26
DASH diet may lower the risk of cardiovascular disease in breast cancer survivors